The battle against COVID-19 is well underway, and now’s the time to send in the big guns. Sorrento Therapeutics (SRNE) is on it, offering both active and passive immunization strategies. As a result, it has received positive investor attention, as demonstrated by its 35% one-month gain.As part of these efforts, the healthcare name, which develops therapies to reduce the malignancy of life-threatening tumors, improves the safety of current treatments and brings solutions to make living with cancer more tolerable, partnered with Celularity. Celularity is a privately-held cell therapeutics company that specializes in transformative allogeneic cellular therapies developed from the postpartum …read more
Source:: Yahoo Finance
